NR3C2 and Hypertension resistant to conventional therapy: The PARAGON‐HF trial showed that the reduction in systolic BP at weeks 4 and 16, respectively, was greater with sacubitril–valsartan vs. valsartan in patients with resistant hypertension (‐4.8 and –3.9 mm Hg) and mineralocorticoid receptor antagonist (MRA)‐resistant hypertension (‐8.8 and ‐6.3 mm Hg).15